Corient Private Wealth LLC Trims Holdings in Kenvue Inc. $KVUE

Corient Private Wealth LLC decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 6.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 471,726 shares of the company’s stock after selling 31,416 shares during the period. Corient Private Wealth LLC’s holdings in Kenvue were worth $8,151,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Hsbc Holdings PLC raised its position in shares of Kenvue by 31.8% during the 4th quarter. Hsbc Holdings PLC now owns 5,106,368 shares of the company’s stock valued at $88,231,000 after purchasing an additional 1,230,957 shares during the period. Reflection Asset Management purchased a new position in shares of Kenvue during the 4th quarter valued at $32,000. Pacer Advisors Inc. boosted its holdings in Kenvue by 7.6% in the 4th quarter. Pacer Advisors Inc. now owns 175,320 shares of the company’s stock worth $3,024,000 after buying an additional 12,338 shares during the period. MV Capital Management Inc. bought a new position in Kenvue in the 4th quarter worth $28,000. Finally, Invesco Ltd. increased its stake in Kenvue by 3.1% in the 4th quarter. Invesco Ltd. now owns 17,551,036 shares of the company’s stock worth $302,755,000 after buying an additional 522,696 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 2.0%

Shares of KVUE stock opened at $18.77 on Thursday. The stock has a market cap of $36.05 billion, a P/E ratio of 22.09, a PEG ratio of 1.40 and a beta of 0.54. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $17.60 and its two-hundred day simple moving average is $17.61.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the firm earned $0.24 EPS. The business’s revenue was up 4.5% on a year-over-year basis. Analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.4%. Kenvue’s dividend payout ratio is presently 97.65%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of recent analyst reports. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group dropped their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Argus upgraded Kenvue to a “hold” rating in a research report on Friday, March 6th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and a consensus target price of $19.33.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.59% of the stock is owned by corporate insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.